Armata Pharmaceuticals (ARMP) EBIT (2013 - 2026)

Armata Pharmaceuticals has disclosed EBIT across 14 years of filings, most recently posting -$10.3 million for Q2 2026.

• In Q2 2026, EBIT fell 50.67% year-over-year to -$10.3 million; the TTM figure through Jun 2026 stood at -$40.7 million (down 15.19% YoY), while the FY2025 annual figure was -$36.6 million, up 13.67% from the prior year.
• EBIT came in at -$10.3 million for Q2 2026 at Armata Pharmaceuticals, down from -$8.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$6.8 million in Q2 2025 to a low of -$13.8 million in Q4 2025.
• Average EBIT over 5 years is -$9.8 million, with a median of -$9.7 million recorded in 2023.
• Year-over-year, EBIT slumped 70.77% in 2022 and jumped 42.55% in 2025.
• Over 5 years, EBIT stood at -$10.3 million in 2022, then rose by 7.25% to -$9.6 million in 2023, then retreated by 10.02% to -$10.5 million in 2024, then slumped by 31.16% to -$13.8 million in 2025, then increased by 25.4% to -$10.3 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$10.3 million in Q2 2026, -$8.8 million in Q1 2026, and -$13.8 million in Q4 2025.